CRISPR-Based Casgevy Emerges as Preferred Gene Therapy for Beta-Thalassemia, Survey Shows
核心洞察
Half of hematologists now favor Casgevy, a CRISPR/Cas9-based gene therapy, over Zynteglo for treating transfusion-dependent β-thalassemia (搜索), according to new physician survey data from Spherix Global Insights (搜索).
Casgevy uses gene editing to reactivate fetal hemoglobin (搜索) production, while Zynteglo employs gene addition via lentiviral vectors to restore normal hemoglobin, with physicians citing different advantages for each approach.
Access barriers including limited treatment center capacity, geographic distance, high costs, and lengthy insurance approvals continue to challenge equitable gene therapy delivery for this severe inherited blood disorder.
A new physician survey reveals a significant shift in hematologist preferences for treating transfusion-dependent β-thalassemia (搜索) (TDT (搜索)), with half of specialists now favoring the CRISPR/Cas9-based therapy Casgevy over the lentiviral vector-based Zynteglo. The data from Spherix Global Insights (搜索)' Market DynamixTM: Transfusion-Dependent Thalassemia survey shows only one-fifth of hematologists prefer Zynteglo, while the remaining respondents express no strong preference between the two gene therapies.
Competing Gene Therapy Approaches
Casgevy (exagamglogene autotemcel), developed by Vertex and CRISPR Therapeutics, employs CRISPR/Cas9 gene editing technology to disable the BCL11A enhancer (搜索), which reactivates the body's natural production of fetal hemoglobin (搜索) (HbF). This oxygen-carrying molecule can compensate for defective β-globin (搜索) in patients with TDT (搜索). Physicians supporting Casgevy cite its "potential for more efficient editing and promising efficacy data," with one physician noting the therapy's "novel CRISPR platform" and accumulating real-world experience as compelling advantages.
In contrast, Zynteglo (betibeglogene autotemcel) from bluebird bio takes a gene addition approach, inserting a functional HBB (搜索) (β-globin (搜索)) gene into a patient's hematopoietic stem cells via a lentiviral vector to restore normal hemoglobin production. Physicians favoring Zynteglo highlight its "higher rate of transfusion independence (90–95% in long-term studies)," "well-established safety profile," and "durable results."
Clinical Decision-Making Factors
The survey data indicates that treatment selection remains highly personalized, with physicians considering multiple factors including patient genotype, treatment center expertise, insurance coverage, and patient or family comfort with each technology platform. Some clinicians view Casgevy as representing a leap forward in precision and efficiency, while others value Zynteglo's longer track record and direct β-globin (搜索) restoration approach.
Notably, the remaining survey respondents who expressed no strong preference cited similar efficacy and safety profiles observed in clinical trials for both therapies, suggesting that clinical outcomes may be comparable between the two approaches.
Access and Implementation Challenges
Despite the therapeutic promise of both gene therapies, significant barriers to access persist across the United States. Physicians in suburban and rural areas report that demand for gene therapy substantially exceeds available treatment capacity. Geographic disparities are particularly pronounced, with hematologists in southern and western regions more likely to cite physical distance to certified gene therapy centers as a major barrier to patient care.
Even when treatment centers are accessible, multiple systemic challenges can delay patient care, including high upfront costs, lengthy insurance approval processes, and constrained treatment slots at certified facilities.
Disease Context and Treatment Impact
TDT (搜索) represents a severe inherited blood disorder that requires patients to undergo lifelong blood transfusions and iron chelation therapy. Gene therapy offers the potential for transfusion independence, representing a transformative treatment option for patients who would otherwise require regular medical interventions throughout their lives.
However, the survey findings underscore that equitable access to these breakthrough therapies remains a critical challenge in the field, potentially limiting the clinical impact of these scientific advances for patients who could benefit from treatment.
Spherix Global Insights (搜索) plans to continue monitoring the hemoglobinopathy market, including thalassemia treatments, through their annual Market DynamixTM and Patient Chart DynamixTM research services to track evolving treatment patterns and access issues in this therapeutic area.